Evidence map›Paper›PMID 30042831›Full record

ArticleOncotarget2018

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Saurabh Agarwal, Giorgio Milazzo, Kimal Rajapakshe, Ronald Bernardi, Zaowen Chen, Barbieri Eveline, Jan Koster, Giovanni Perini, Cristian Coarfa, Jason M Shohet

Open access · diamondAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. The roles of glucose metabolic reprogramming in chemo- and radio-resistance.Journal of experimental & clinical cancer research : CR · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Saurabh AgarwalDivision of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Giorgio MilazzoDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Kimal RajapaksheDan L Duncan Cancer Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Ronald BernardiDivision of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Zaowen ChenDivision of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Barbieri EvelineDivision of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Jan KosterDepartment of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Giovanni PeriniDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Cristian CoarfaDan L Duncan Cancer Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Jason M ShohetDivision of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Baylor College of Medicine · USUniversity of Bologna · ITAcademic Medical Center · NL

Funding

Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cellsR01CA174808 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SHOHET, JASON M · 2014 to 2018
$1.7M
NCI NIH HHS R01 CA174808
6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.24859.].

Identifiers

PMID30042831
PMCPMC6057463
OpenAlexW2829518215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.